As of 2025-06-12, the Fair Value of ProQR Therapeutics NV (PRQR) is -2.46 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 1.82 USD, the upside of ProQR Therapeutics NV is -235.23%.
With the market price of 1.82 USD and our fair value calculation, ProQR Therapeutics NV (PRQR) is not a good investment. Investing in PRQR stocks now will result in a potential loss of 235.23%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | -46.57 | -61.62 | -65.11 | -28.12 | -27.76 | -45.84 |
| YoY growth | 17.55% | -32.32% | -5.66% | 56.81% | 1.27% | 7.53% |
| Market Cap (mil) | 191.48 |
| P/E | |
| Forward P/E |
| EPS | -0.29 |
| Avg earnings growth rate | 7.53% |
| TTM earnings | -30.18 |